Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 4
2022 2
2023 1
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean muanza b (14 results)?
Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Musiime V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, Mujuru HA, Kityo CM, Lugemwa A, Doerholt K, Chabala C, Makumbi S, Mulenga V, McIlleron H, Burger D, Natukunda E, Shakeshaft C, Linda KJ, Nathoo K, Monkiewicz L, Yawe I, Kapasa M, Nyathi M, Lungu J, Nduna B, Ndebele W, South A, Mwamabazi M, Musoro G, Griffiths A, Zyambo K, Nazzinda R, Zimba K, Zhang Y, Walker S, Turkova A, Walker AS, Bamford A, Gibb DM; CHAPAS-4 Trial Team. Musiime V, et al. N Engl J Med. 2025 May 15;392(19):1917-1932. doi: 10.1056/NEJMoa2404597. N Engl J Med. 2025. PMID: 40367375 Free PMC article. Clinical Trial.
Routine HIV clinic visit adherence in the African Cohort Study.
Dear N, Esber A, Iroezindu M, Bahemana E, Kibuuka H, Maswai J, Owuoth J, Polyak CS, Ake JA, Crowell TA; AFRICOS Study Group. Dear N, et al. AIDS Res Ther. 2022 Jan 7;19(1):1. doi: 10.1186/s12981-021-00425-0. AIDS Res Ther. 2022. PMID: 34996470 Free PMC article.
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa.
Katongole F, Arumugam T, Jennings A, Mutata C, Ssebunya P, Wamboi C, Green A, Bwakura-Dangarembizi M, Kityo C, Siika A, Archary M, Jafta L, Namukwaya S, Seeley J, Mugerwa H, Walker S, Apoto N, Thomason MJ, Ford D, Pett SL, Kekitiinwa AR; BREATHER Plus trial team. Katongole F, et al. Contemp Clin Trials. 2025 Aug;155:107963. doi: 10.1016/j.cct.2025.107963. Epub 2025 May 29. Contemp Clin Trials. 2025. PMID: 40449658 Free PMC article.
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.
Bevers LAH, Toledo G, Kisekka M, Kaudha E, Ahimbisibwe GM, Deprez I, Arumugan T, Variava E, Violari A, White I, Bbuye D, Nanduudu A, Mulwanyi E, Amuge P, Rutebarika DA, Kekitiinwa A, Kityo C, Musoke P, Archary M, Boles J, Thomason MJ, de Wildt SN, Giaquinto C, Colbers A, Burger DM, Buchanan AM, Chan MK, Jacobs TG, Turkova A; D3 TRIAL TEAM. Bevers LAH, et al. EBioMedicine. 2025 Oct;120:105929. doi: 10.1016/j.ebiom.2025.105929. Epub 2025 Sep 26. EBioMedicine. 2025. PMID: 41014973 Free PMC article. Clinical Trial.
Epidemiology of Tuberculosis Among People Living With HIV in the African Cohort Study From 2013 to 2021.
Ganesan K, Mwesigwa R, Dear N, Esber AL, Reed D, Kibuuka H, Iroezindu M, Bahemana E, Owuoth J, Singoei V, Maswai J, Parikh AP, Crowell TA, Ake JA, Polyak CS, Shah N, Cavanaugh JS; AFRICOS Study Group; AFRICOS Study Group. Ganesan K, et al. J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):359-369. doi: 10.1097/QAI.0000000000003152. Epub 2023 Jan 3. J Acquir Immune Defic Syndr. 2023. PMID: 36728618 Free PMC article.
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.
Wieczorek L, Chang D, Sanders-Buell E, Zemil M, Martinez E, Schoen J, Chenine AL, Molnar S, Barrows B, Poltavee K, Charurat ME, Abimiku A, Blattner W, Iroezindu M, Kokogho A, Michael NL, Crowell TA, Ake JA, Tovanabutra S, Polonis VR; AFRICOS and TRUST/RV368 Study Groups. Wieczorek L, et al. Virol J. 2024 Jun 29;21(1):148. doi: 10.1186/s12985-024-02394-y. Virol J. 2024. PMID: 38951814 Free PMC article.
13 results